You can sign into the Live Stream starting at 11:00 am ET by visiting https://practicingclinicians.com/symposia/register/covid-19-webinar-october-6-1 Live Stream Practicing Clinicians Exchange false
- Current state of COVID-19
- Timely COVID-19 diagnostic and treatment strategies
- Risk stratification and timely determination of candidates for antiviral treatment
- Current landscape of COVID-19 antiviral therapies
- Benefits of early outpatient antiviral therapy for mitigation of SARS-CoV-2 deleterious consequences (eg, acute and long-term sequelae)
- Question and answer session
- Director, International HIV Training Center
- Professor of Medicine
- Section of Infectious Diseases and Global Health
- Department of Medicine
- University of Chicago
- Chicago, Illinois
- Clinical Pharmacy Specialist in Infectious Diseases
- Department of Pharmaceutical Services
- Emory University Hospital Midtown
- Atlanta, Georgia
The goal of this activity is to improve healthcare professionals’ knowledge and competence and foster an interprofessional approach for early SARS-CoV-2 diagnosis and treatment in the outpatient setting to mitigate severe and long-term consequences of COVID-19.
This program is intended for physicians, nurses, NPs, PAs, pharmacists, and other healthcare professionals involved in the management of patients with COVID-19, including both specialists and primary care providers. This identified target audience will benefit from this education by gaining the knowledge and strategies necessary to individualize early outpatient COVID-19 management.
After completing this activity, participants should be better able to:
- Recognize the need for timely COVID-19 testing, diagnosis, and risk stratification at or before the onset of symptoms
- Describe the rationale for outpatient SARS-CoV-2 antiviral therapy early in the disease course
- Identify candidates for early outpatient treatment with SARS‑CoV‑2 antivirals based on determinants associated with adverse outcomes including risk factors for severe illness and health disparities
- Select the appropriate antiviral treatment for COVID-19 patients based on patient factors, guidelines, and current scientific evidence
- Apply strategies to promote timely and equitable administration of SARS-CoV-2 antivirals
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO), ProCE, LLC, and Practicing Clinicians Exchange. CCO is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Designation of Credit
CCO designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-9999-22-205-L01-P
Type of Activity: Application
Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO), ProCE, LLC, and Practicing Clinicians Exchange (PCE), require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO, ProCE, and PCE policy. CCO, ProCE, and PCE are committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
Americans With Disabilities Act
Supported by educational grants from Gilead Sciences, Inc., and Merck Sharp & Dohme Corp.